(Q80403726)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16033292%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

review article

1 reference

title

Posaconazole (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16033292%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Gillian M Keating

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16033292%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

1 January 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16033292%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16033292%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

65

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16033292%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16033292%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

1553-67; discussion 1568-9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16033292%20AND%20SRC:MED&resulttype=core&format=json

In vitro antifungal susceptibilities of Trichosporon species.

31 December 2019

cites work

1 reference

12 December 2020

A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).

1 reference

12 December 2020

Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase

1 reference

12 December 2020

Antifungal therapy of murine Aspergillus terreus infection

1 reference

12 December 2020

Efficacy of SCH56592 in a rabbit model of invasive aspergillosis

1 reference

12 December 2020

Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection

1 reference

12 December 2020

In vitro and in vivo activities of posaconazole against Coccidioides immitis

1 reference

12 December 2020

Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.

1 reference

12 December 2020

Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia

1 reference

12 December 2020

Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis

1 reference

12 December 2020

Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice.

1 reference

12 December 2020

Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection

1 reference

12 December 2020

Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy

1 reference

12 December 2020

In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis

1 reference

12 December 2020

Treatment of Scedosporium apiospermum brain abscesses with posaconazole

1 reference

12 December 2020

Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera

1 reference

12 December 2020

Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men

1 reference

12 December 2020

Systemic mycoses in the immunocompromised host: an update in antifungal therapy

1 reference

12 December 2020

Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study

1 reference

12 December 2020

Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole

1 reference

12 December 2020

SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei")

1 reference

12 December 2020

Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus

1 reference

12 December 2020

Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays

1 reference

12 December 2020

In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans

1 reference

12 December 2020

In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida

1 reference

12 December 2020

Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease

1 reference

12 December 2020

Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding.

1 reference

12 December 2020

Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds

1 reference

12 December 2020

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

1 reference

12 December 2020

Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories

1 reference

12 December 2020

Treatment of murine fusariosis with SCH 56592

1 reference

12 December 2020

Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient

1 reference

12 December 2020

Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans

1 reference

12 December 2020

In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients

1 reference

12 December 2020

A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans

1 reference

12 December 2020

Azole cross-resistance in Aspergillus fumigatus

1 reference

12 December 2020

Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus

1 reference

12 December 2020

Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B.

1 reference

12 December 2020

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

1 reference

12 December 2020

Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo

1 reference

12 December 2020

In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model

1 reference

12 December 2020

Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis

1 reference

12 December 2020

Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice

1 reference

12 December 2020

In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program

1 reference

12 December 2020

Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil).

1 reference

12 December 2020

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

1 reference

12 December 2020

Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy

1 reference

12 December 2020

Posaconazole therapy of disseminated phaeohyphomycosis in a murine model

1 reference

12 December 2020

Disposition of posaconazole following single-dose oral administration in healthy subjects

1 reference

12 December 2020

Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis

1 reference

12 December 2020

Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.

1 reference

12 December 2020

SCH56592 treatment of murine invasive aspergillosis

1 reference

12 December 2020

Efficacy of posaconazole in a murine model of central nervous system aspergillosis

1 reference

12 December 2020

Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations

1 reference

12 December 2020

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

1 reference

12 December 2020

Activity of posaconazole in treatment of experimental disseminated zygomycosis.

1 reference

12 December 2020

Changes in susceptibility to posaconazole in clinical isolates of Candida albicans

1 reference

12 December 2020

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

1 reference

12 December 2020

In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans

1 reference

12 December 2020

Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole

1 reference

12 December 2020